Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une première étude humaine de KK2223 chez les participants atteints de lymphome non hodgkinien en rechute ou réfractaire

29 septembre 2026 mis à jour par: Kyowa Kirin, Inc.

Une phase 1, multicentrique, en ouvert, non randomisée, à l'escalade de dose et à un remblai de KK2223 chez les participants avec un lymphome non hodgkinaire à cellules T rechutée ou réfractaire

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

Type d'étude

Interventionnel

Inscription (Estimé)

72

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Madrid, Espagne, 28027
        • Pas encore de recrutement
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • Contact:
          • Miguel Canales Albendea
          • Numéro de téléphone: 34917277116
          • E-mail: macanales@unav.es
        • Chercheur principal:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, Espagne, 8036
        • Pas encore de recrutement
        • Hospital Clinic De Barcelona - Hematología
        • Chercheur principal:
          • Pablo Mozas
        • Contact:
      • L'Hospitalet de Llobregat, Barcelona, Espagne, 8907
        • Pas encore de recrutement
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • Chercheur principal:
          • Eva Domingo Domenech
        • Contact:
    • Navarre
      • Pamplona, Navarre, Espagne, 31008
        • Pas encore de recrutement
        • Clinica Universidad de Navarra - Hematología
        • Contact:
          • Miguel Canales Albendea
          • Numéro de téléphone: 34917277116
          • E-mail: macanales@unav.es
        • Chercheur principal:
          • Miguel Canales Albendea
      • Bergamo, Italie, 24127
        • Pas encore de recrutement
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • Chercheur principal:
          • Giuseppe Gritti
        • Contact:
      • Bologna, Italie, 40138
        • Pas encore de recrutement
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • Contact:
        • Chercheur principal:
          • Luigi Zinzani Pier
      • Torino, Italie, 10126
        • Pas encore de recrutement
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • Contact:
        • Chercheur principal:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, Italie, 10060
        • Pas encore de recrutement
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • Chercheur principal:
          • Umberto Vitolo
        • Contact:
    • California
      • Duarte, California, États-Unis, 91010
        • Pas encore de recrutement
        • City of Hope
        • Chercheur principal:
          • Christina Poh
        • Contact:
          • Christina Poh
          • Numéro de téléphone: 916-734-7131
          • E-mail: cpoh@coh.org
      • Orange, California, États-Unis, 92868
        • Pas encore de recrutement
        • University of California, Irvine Medical Center - Hematology/Oncology
        • Contact:
          • Lauren Pinter Brown
          • Numéro de téléphone: 7144568200
          • E-mail: lpinterb@uci.edu
        • Chercheur principal:
          • Lauren Pinter Brown
      • Stanford, California, États-Unis, 94305
        • Recrutement
        • Stanford University School of Medicine
        • Chercheur principal:
          • Youn Kim
        • Contact:
    • Florida
      • Tampa, Florida, États-Unis, 33612
        • Pas encore de recrutement
        • Moffit Cancer Center
        • Contact:
        • Chercheur principal:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Pas encore de recrutement
        • Emory University Medical Center
        • Chercheur principal:
          • Pamela Allen
        • Contact:
    • Iowa
      • Iowa City, Iowa, États-Unis, 52242
        • Pas encore de recrutement
        • University of Iowa Health
        • Chercheur principal:
          • Eric Mou
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Pas encore de recrutement
        • Beth Israel Deaconess Medical Center - Research
        • Contact:
        • Chercheur principal:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine - Oncology Hospital - Public
        • Chercheur principal:
          • Neha Mehta Shah
        • Contact:
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601-2105
        • Pas encore de recrutement
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • Chercheur principal:
          • Tatyana Feldman
        • Contact:
    • New York
      • New York, New York, États-Unis, 10021-6007
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
        • Chercheur principal:
          • Jasmine Zain
        • Contact:
    • Ohio
      • Cleveland, Ohio, États-Unis, 44106
        • Pas encore de recrutement
        • University Hospitals Cleveland Medical Center
        • Contact:
        • Chercheur principal:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Pas encore de recrutement
        • Oregon Health & Science University
        • Contact:
        • Chercheur principal:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Pas encore de recrutement
        • University of Pennsylvania - Abramson Cancer Center
        • Chercheur principal:
          • Stefan Barta
        • Contact:
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • The University of Texas - MD Anderson Cancer Center
        • Chercheur principal:
          • Ranjit Nair
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

Expérimental: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mean Blood Drug Concentration
Délai: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
Délai: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Délai: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Délai: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Délai: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Délai: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
Délai: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Délai: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

2 septembre 2026

Achèvement primaire (Estimé)

1 mars 2029

Achèvement de l'étude (Estimé)

1 septembre 2030

Dates d'inscription aux études

Première soumission

12 août 2025

Première soumission répondant aux critères de contrôle qualité

17 septembre 2025

Première publication (Réel)

25 septembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

29 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner